Document Type : Original Article(s)
Authors
- Seyedali Momeni 1
- Mohsen Ayati 1
- Erfan Amini 1
- Seyed Hassan Inanloo 1
- Mohammad Hamidi Madani 1
- Ehsan Hajiasadi 1, 2, 3
- Farzeen Ghaderpanah 1
- Mohammad Reza Nowroozi 1
1 Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran
2 Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran
3 School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
Abstract
Background: Prostate cancer (PCa) remains one of the most common malignancies among men worldwide, with lymph node invasion (LNI) serving as a critical prognostic factor influencing treatment decisions and outcomes. This study aimed to evaluate the prevalence of LNI and investigate associated risk factors in a cohort of intermediate-risk PCa patients.
Methods: This retrospective cross-sectional study included intermediate-risk PCa patients treated at Imam Khomeini Hospital, Tehran, Iran, from 2019 to 2024, who underwent radical prostatectomy with pelvic lymph node dissection (PLND). Data were extracted from hospital clinical documents and compared between patients with and without LNI. The primary outcome was the prevalence of LNI, while the secondary outcome aimed to identify associated demographic, clinical, and pathological risk factors. Statistical tests such as univariate logistic regression and ROC curve analysis were used.
Results: This study found a 12.10% prevalence of LNI. Univariate analysis revealed significant associations between LNI and advanced clinical stage, higher Gleason score, greater core involvement, and elevated total prostate-specific antigen (PSA) (OR=1.33), with all P<0.05. In multiple logistic regression analysis, adjusting for confounders, only PSA remained an independent predictor. The receiver operating characteristic (ROC) analysis confirmed PSA’s moderate diagnostic accuracy for LNI (area under the curve [AUC]=0.685, P<0.001), with an optimal cut-off of 16.52 ng/mL, 65% sensitivity, and 68% specificity.
Conclusion: The results indicated that only total PSA remained an independent predictor. This finding highlighted total PSA as a key biomarker for assessing LNI risk in intermediate-risk PCa patients. Additionally, total PSA demonstrated moderate diagnostic accuracy in predicting LNI, supporting its clinical utility in risk stratification and decision-making.
Highlights
Seyedali Momeni (Google Scholar)
Mohammad Reza Nowroozi (Google Scholar)
Keywords
- Ghaderi R, Abdollahi Z, Madani MH, Doshantapeh AG, Moghimi B, Jarang M, et al. Association between serum vitamin D levels and prostate tumor: a systematic review and meta-analysis. J Renal Inj Prev. 2024;13:e34296. doi: 10.34172/jrip.2024.34296.
- Nourmohammadi A, A SA, K RA, B SQ, A RJ, Roohinezhad R, et al. The association between systemic immune-inflammation index and risk of prostate carcinoma; a systematic review and meta-analysis. Immunopathol Persa. 2025;11:e43810. doi: 10.34172/ipp.2025.43810.
- Xu H, Zhu Y, Dai B, Ye DW. National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients. Asian J Androl. 2018;20:551-4. doi: 10.4103/aja.aja_52_18. PubMed PMID: 30027928; PubMed Central PMCID: PMC6219292.
- Seiden B, Weng S, Sun N, Gordon D, Harris WN, Barnett J, et al. NCCN Risk Reclassification in Black Men with Low and Intermediate Risk Prostate Cancer After Genomic Testing. Urology. 2022;163:81-9. doi: 10.1016/j.urology.2021.08.055. PubMed PMID: 34688772.
- Nezolosky M, Nguyen PL, Yang DD. Which patients with localized prostate cancer account for the greatest proportion of prostate cancer deaths? J Clin Oncol. 2018;36:130. doi: 10.1200/JCO.2018.36.6_suppl.130.
- Diven MA, Tshering L, Ma X, Hu JC, Barbieri C, McClure T, et al. Trends in Active Surveillance for Men With Intermediate-Risk Prostate Cancer. JAMA Netw Open. 2024;7:e2429760. doi: 10.1001/jamanetworkopen.2024.29760. PubMed PMID: 39172448; PubMed Central PMCID: PMC11342134.
- Harryman WL, Hinton JP, Sainz R, Gard JMC, Ryniawec JM, Rogers GC, et al. Intermediate risk prostate tumors contain lethal subtypes. Front Urol. 2024;4. doi: 10.3389/fruro.2024.1487873. PubMed PMID: 40129601; PubMed Central PMCID: PMC11932713.
- Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013;64:895-902. doi: 10.1016/j.eururo.2013.03.033. PubMed PMID: 23541457.
- Perera M, Lebdai S, Tin AL, Sjoberg DD, Benfante N, Beech BB, et al. Oncologic outcomes of patients with lymph node invasion at prostatectomy and post-prostatectomy biochemical persistence. Urol Oncol. 2023;41:105. doi: 10.1016/j.urolonc.2022.10.021. PubMed PMID: 36435708; PubMed Central PMCID: PMC10391319.
- Tafuri A, Rizzetto R, Amigoni N, Sebben M, Shakir A, Gozzo A, et al. Predictors of Lymph Node Invasion in Patients with Clinically Localized Prostate Cancer Who Undergo Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: The Role of Obesity. Urol Int. 2021;105:362-9. doi: 10.1159/000510008. PubMed PMID: 33059351.
- Wenzel M, Preisser F, Hoeh B, Welte MN, Humke C, Wittler C, et al. Influence of Biopsy Gleason Score on the Risk of Lymph Node Invasion in Patients With Intermediate-Risk Prostate Cancer Undergoing Radical Prostatectomy. Front Surg. 2021;8:759070. doi: 10.3389/fsurg.2021.759070. PubMed PMID: 34957202; PubMed Central PMCID: PMC8695544.
- Maccio L, Barresi V, Domati F, Martorana E, Cesinaro AM, Migaldi M, et al. Clinical significance of pelvic lymph node status in prostate cancer: review of 1690 cases. Intern Emerg Med. 2016;11:399-404. doi: 10.1007/s11739-015-1375-5. PubMed PMID: 26875178.
- Hori S, Nakai Y, Tachibana A, Omori C, Nishimura N, Inoue K, et al. Clinical significance of limited and extended pelvic lymph node dissection during robot-assisted radical prostatectomy for patients with localized prostate cancer: A retrospective, propensity score matching analysis. Int J Urol. 2023;30:168-75. doi: 10.1111/iju.15075. PubMed PMID: 36305671.
- Porcaro AB, de Luyk N, Corsi P, Sebben M, Tafuri A, Mattevi D, et al. Clinical Factors Predicting and Stratifying the Risk of Lymph Node Invasion in Localized Prostate Cancer. Urol Int. 2017;99:207-14. doi: 10.1159/000458763. PubMed PMID: 28245480.
- Xu N, Ke ZB, Chen YH, Wu YP, Chen SH, Wei Y, et al. Risk Factors for Pathologically Confirmed Lymph Nodes Metastasis in Patients With Clinical T2N0M0 Stage Prostate Cancer. Front Oncol. 2020;10:1547. doi: 10.3389/fonc.2020.01547. PubMed PMID: 32923401; PubMed Central PMCID: PMC7456999.
- Chen J, Wang Z, Zhao J, Zhu S, Sun G, Liu J, et al. Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database. Sci Rep. 2019;9:17985. doi: 10.1038/s41598-019-54261-4. PubMed PMID: 31784574; PubMed Central PMCID: PMC6884595.
- Pollard ME, Hobbs AR, Kwon YS, Katsigeorgis M, Lavery HJ, Levinson A, et al. Heterogeneity of Outcomes in D’Amico Intermediate-Risk Prostate Cancer Patients after Radical Prostatectomy: Influence of Primary and Secondary Gleason Score. Oncol Res Treat. 2017;40:508-14. doi: 10.1159/000477545. PubMed PMID: 28796995.
- Behmueller M, Tselis N, Zamboglou N, Zoga E, Baltas D, Rodel C, et al. High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up. Front Oncol. 2021;11:770959. doi: 10.3389/fonc.2021.770959. PubMed PMID: 34926278; PubMed Central PMCID: PMC8674679.
- Porcaro AB, Corsi P, Inverardi D, Sebben M, Tafuri A, Processali T, et al. Prostate-specific antigen associates with extensive lymph node invasion in high-risk prostate cancer. Tumori. 2018;104:307-11. doi: 10.1177/0300891618765567. PubMed PMID: 29714659.
- Porcaro AB, De Luyk N, Corsi P, Sebben M, Tafuri A, Processali T, et al. Clinical Factors Predicting Bilateral Lymph Node Invasion in High-Risk Prostate Cancer. Urol Int. 2017;99:392-9. doi: 10.1159/000476039. PubMed PMID: 28486228.
- Wang X, Zhang X, Li H, Zhang M, Liu Y, Li X. Application of machine learning algorithm in prediction of lymph node metastasis in patients with intermediate and high-risk prostate cancer. J Cancer Res Clin Oncol. 2023;149:8759-68. doi: 10.1007/s00432-023-04816-w. PubMed PMID: 37127828; PubMed Central PMCID: PMC10374763.
- Winter A, Kneib T, Wasylow C, Reinhardt L, Henke RP, Engels S, et al. Updated Nomogram Incorporating Percentage of Positive Cores to Predict Probability of Lymph Node Invasion in Prostate Cancer Patients Undergoing Sentinel Lymph Node Dissection. J Cancer. 2017;8:2692-8. doi: 10.7150/jca.20409. PubMed PMID: 28928857; PubMed Central PMCID: PMC5604200.
- Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol. 2012;61:480-7. doi: 10.1016/j.eururo.2011.10.044. PubMed PMID: 22078338.
- Shida Y, Hakariya T, Mitsunari K, Matsuo T, Ohba K, Miyata Y, et al. Preoperative Predictors of Lymph Node Invasion and Biochemical Recurrence in High-risk Prostate Cancer. Cancer Diagn Progn. 2022;2:49-54. doi: 10.21873/cdp.10075. PubMed PMID: 35400005; PubMed Central PMCID: PMC8962846.
- Heidenreich A, Pfister D, Thuer D, Brehmer B. Percentage of positive biopsies predicts lymph node involvement in men with low-risk prostate cancer undergoing radical prostatectomy and extended pelvic lymphadenectomy. BJU Int. 2011;107:220-5. doi: 10.1111/j.1464-410X.2010.09485.x. PubMed PMID: 20590538.
- Gandaglia G, Martini A, Ploussard G, Fossati N, Stabile A, De Visschere P, et al. External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. Eur Urol. 2020;78:138-42. doi: 10.1016/j.eururo.2020.03.023. PubMed PMID: 32268944.
- Briganti A, Capitanio U, Abdollah F, Gallina A, Suardi N, Bianchi M, et al. Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool. Prostate. 2012;72:499-506. doi: 10.1002/pros.21451. PubMed PMID: 22468270.
- Spangler E, Zeigler-Johnson CM, Malkowicz SB, Wein AJ, Rebbeck TR. Association of prostate cancer family history with histopathological and clinical characteristics of prostate tumors. Int J Cancer. 2005;113:471-4. doi: 10.1002/ijc.20578. PubMed PMID: 15455347.
- da Cruz JAS, Passerotti CC, Dos Reis ST, Guariero MES, de Campos OD, Leite KRM, et al. Is Age an Independent Factor for Prostate Cancer? A Paired Analysis. Curr Urol. 2017;9:183-7. doi: 10.1159/000447138. PubMed PMID: 28413378; PubMed Central PMCID: PMC5385861.
- Briganti A, Karakiewicz PI, Chun FK, Suardi N, Gallina A, Abdollah F, et al. Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection. Int J Urol. 2009;16:676-81. doi: 10.1111/j.1442-2042.2009.02330.x. PubMed PMID: 19602006.
- Hong SK, Poon BY, Sjoberg DD, Scardino PT, Eastham JA. Prostate size and adverse pathologic features in men undergoing radical prostatectomy. Urology. 2014;84:153-7. doi: 10.1016/j.urology.2014.04.006. PubMed PMID: 24976228; PubMed Central PMCID: PMC4076683.
)